Integrated DNA Technologies NBS CF Reagents

The Colorado Department of Public Health and Environment, Laboratory Services Division, is procuring sequencing library preparation reagents for the Colorado Newborn Screening Program on a sole source basis from Integrated DNA Technologies (IDT). This procurement covers the xGen CFTR Amplicon kit, a proprietary product used exclusively for next-generation sequencing (NGS) testing of cystic fibrosis in newborn screening samples. The contract will run for five years from May 1, 2026 through May 1, 2031, with an estimated total project cost of $375,000. The evaluation process, conducted between February 2024 and October 2025, assessed multiple vendors and products including IDT's Archer line at $155 per sample and Illumina's TruSight CFTR kit at $37.38 per sample before selecting IDT's xGen Amplicon at $47.59 per sample. The selection was based on IDT's exclusive manufacture of the xGen CFTR Amplicon reagents and the validated compatibility of this product with the Colorado Newborn Screening Program's existing workflows, instrumentation, and bioinformatics pipeline. The procurement opportunity was posted on April 13, 2026, with a response deadline of April 16, 2026. Key evaluation criteria included cost efficiency, sample type compatibility requirements, and integration with the State Laboratory Genomics program's existing instruments and infrastructure.

This is a sole source procurement, which restricts competition to Integrated DNA Technologies as the exclusive vendor capable of supplying the required xGen CFTR Amplicon kit. The justification for sole source procurement is based on the exclusive availability and proprietary nature of IDT's product and its validated compatibility with the program's existing genomics infrastructure. No set-aside designations for disadvantaged enterprises or other organizational restrictions are indicated in the procurement documentation. The estimated contract value is $375,000 over the five-year performance period, representing the total budget allocation for the reagent procurement. Integration requirements are substantial, as the selected product must maintain compatibility with the Colorado Newborn Screening Program's current NGS workflows, laboratory instrumentation, and established bioinformatics analysis pipeline.